Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more
Bal Pharma Limited (BALPHARMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.129x
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has a cash flow conversion efficiency ratio of 0.129x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹101.16 Million) by net assets (₹783.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bal Pharma Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Bal Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bal Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bal Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tarmat Limited
NSE:TARMAT
|
0.016x |
|
Skin Elements Ltd
AU:SKN
|
-0.699x |
|
Panatlântica S.A
SA:PATI3
|
0.069x |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
0.159x |
|
Better Choice Company Inc
NYSE MKT:BTTR
|
0.048x |
|
Agro Phos India Limited
NSE:AGROPHOS
|
0.113x |
|
Asra Minerals Ltd
AU:ASR
|
-0.050x |
|
Trisula International Tbk
JK:TRIS
|
0.121x |
Annual Cash Flow Conversion Efficiency for Bal Pharma Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Bal Pharma Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹774.04 Million | ₹42.32 Million | 0.055x | -83.39% |
| 2024-03-31 | ₹692.61 Million | ₹228.06 Million | 0.329x | +1237.80% |
| 2023-03-31 | ₹637.02 Million | ₹-18.43 Million | -0.029x | -106.11% |
| 2022-03-31 | ₹584.92 Million | ₹277.08 Million | 0.474x | +16.04% |
| 2021-03-31 | ₹533.54 Million | ₹217.81 Million | 0.408x | -19.88% |
| 2020-03-31 | ₹453.38 Million | ₹231.01 Million | 0.510x | +295.55% |
| 2019-03-31 | ₹602.21 Million | ₹77.58 Million | 0.129x | +1663.52% |
| 2018-03-31 | ₹602.01 Million | ₹-4.96 Million | -0.008x | -108.44% |
| 2017-03-31 | ₹600.31 Million | ₹58.58 Million | 0.098x | +127.59% |
| 2016-03-31 | ₹547.22 Million | ₹-193.53 Million | -0.354x | -234.25% |
| 2015-03-31 | ₹551.68 Million | ₹145.33 Million | 0.263x | -0.97% |
| 2014-03-31 | ₹500.50 Million | ₹133.13 Million | 0.266x | -27.36% |
| 2013-03-31 | ₹446.18 Million | ₹163.39 Million | 0.366x | +14.07% |
| 2012-03-31 | ₹400.56 Million | ₹128.58 Million | 0.321x | +151.97% |
| 2011-03-31 | ₹361.75 Million | ₹46.09 Million | 0.127x | +187.92% |
| 2010-03-31 | ₹357.62 Million | ₹-51.82 Million | -0.145x | -142.27% |
| 2009-03-31 | ₹372.35 Million | ₹127.64 Million | 0.343x | +32.33% |
| 2008-03-31 | ₹350.32 Million | ₹90.75 Million | 0.259x | +67.86% |
| 2007-03-31 | ₹334.02 Million | ₹51.55 Million | 0.154x | +183.48% |
| 2006-03-31 | ₹323.02 Million | ₹-59.71 Million | -0.185x | -- |